How to Read Mounjaro and Zepbound Records

TL;DR

• The FDA label for Zepbound names tirzepatide and lists NDA 217806, tying that molecule and application number to the product record.¹
• The FDA label for Mounjaro names tirzepatide and lists NDA 215866, tying that molecule and application number to the product record.²
• Mounjaro’s original application was approved in 2022, while Zepbound’s original application was approved in 2023 under its separate record.³
• A review describes tirzepatide as an agonist at both GIP and GLP-1 receptors, which is why the mechanism is called dual.⁴

For readers in the Philippines, US brand names often appear together in health stories. Start by separating the molecule from each named product. The two FDA records name tirzepatide, but each has its own application number.¹ That difference helps readers trace a statement to the right source. It also keeps a brand label from becoming a summary of every study involving the molecule. This guide compares source types without turning product identity into a claim about personal outcomes.

Start with identity: one molecule, two records

The FDA label for Zepbound names tirzepatide and lists NDA 217806.¹ The FDA label for Mounjaro also names tirzepatide and lists NDA 215866.² The molecule is the shared scientific identity. The application numbers identify separate product records. Their original approval dates also differ: May 13, 2022, for Mounjaro and November 8, 2023, for Zepbound.³ These details support a narrow conclusion. The two records concern products with the same named active molecule, but readers should trace label statements to the correct file. A molecule-level study may add context, yet it does not merge the records. Identity tells readers what molecule appears in each file. Record numbers tell them where to verify a product-specific detail.

Tirzepatide is named here as a neutral catalog reference.¹

Why separate records matter

A product name, active molecule, and regulatory file answer different questions. The FDA record for Zepbound ties that name to tirzepatide and NDA 217806.¹ The Mounjaro record ties its name to tirzepatide and NDA 215866.² When an article says “same molecule,” it is describing chemical identity. It is not quoting every detail from both labels. When an article gives an approval date, it should name the related product. The same care applies to application numbers. This method prevents a true detail from being attached to the wrong record. It also creates a clear reading order: identify the product, open its source, then check the exact claim.

What dual agonist means

A review describes tirzepatide as an agonist at both GIP and GLP-1 receptors.⁴ An agonist activates receptor signaling. “Dual” means that two receptor systems are involved.⁴ This mechanism can help explain why researchers study the molecule across several metabolic questions. It cannot replace direct evidence for a clinical outcome. The review itself calls for longer and real-world research on broader uses.⁴ Mechanism and outcome therefore belong in different columns. A receptor description tells readers what signaling is involved. A randomized trial tests outcomes under a set protocol. Keeping those roles separate makes technical language easier to assess. It also limits the common leap from a biological pathway to a promised result.

Human trials answer defined questions

One phase 3 trial enrolled 206 Chinese adults with early type 2 diabetes at 29 centers.⁵ Participants received tirzepatide or placebo for 40 weeks.⁵ The tirzepatide groups had larger falls in HbA1c and body weight.⁵ Gastrointestinal events were the most common treatment-emergent adverse events, and Eli Lilly funded the study.⁵ Those results belong to that population and protocol.

A separate 72-week randomized trial studied 201 Japanese adults with obesity disease without diabetes.⁶ Several physical and psychosocial quality-of-life scores improved more with tirzepatide than with placebo.⁶ The trial used patient-reported outcomes, which capture participants’ views of health and daily function.⁶ The two trials studied different people and measures. Reading them together can broaden context, but it should not erase those differences.

Comparisons depend on design

A systematic review pooled 45 randomized trials in adults with type 2 diabetes or obesity.⁷ It analyzed tirzepatide and semaglutide separately rather than through one direct head-to-head trial.⁷ Coronary estimates for tirzepatide were less precise because those trials had fewer events and limited coronary data.⁷ The result shows why a pooled comparison needs careful wording.

Another study used matched electronic health records from adults with obesity and heart failure with preserved ejection fraction.⁸ Over a median 24 weeks, it found no observed difference in death or heart-failure hospitalization between the two groups.⁸ The study was observational, so residual confounding may remain.⁸ A short matched record study and a randomized trial do not offer the same control. Readers should check design, follow-up, population, and outcome before comparing conclusions.

Small signals need modest conclusions

A retrospective controlled study followed 60 adults with obesity for two months.⁹ Tirzepatide exposure was associated with lower BMI and mean platelet volume.⁹ Mean platelet volume is an average size measure, not a direct test of platelet function.⁹ The study lacked direct inflammatory and platelet-function markers.⁹ Its authors treated the result as a starting point for more research.⁹

A case report described a 25-year-old woman with hypersensitivity confirmed through intradermal testing.¹⁰ She later tolerated a supervised semaglutide challenge.¹⁰ The clinical detail can help form a research question. Still, one case cannot estimate how often an event occurs or predict another person’s response.¹⁰ Sample size changes what a source can support. A small study may show an association, while a single case records one event.

Records can measure documentation

A US electronic-health-record study compared medication status in clinical notes with structured prescription records.¹¹ Persistence estimates were lower when researchers used the notes.¹¹ A prescription can record intent without confirming that treatment began or continued.¹¹ The team used an LLM-assisted process checked against physician-reviewed events.¹¹ That method adds another layer to assess: how the records were extracted and classified. A note-based result depends on what clinicians documented. It also depends on how the study converted that text into events. These points explain why a record-based estimate measures recorded care.

An editorial survey found 33 compounded semaglutide or tirzepatide products with formulations that differed from FDA-approved products.¹² The survey did not test the products through clinical or laboratory analysis.¹² Its authors said safety and efficacy for those forms were largely unknown.¹² A familiar molecule name does not settle questions about formulation. Source type, product identity, and testing method still matter.

Semaglutide is named here as a neutral catalog reference.⁷

Lab work stays in its lane

A preprint combined mouse experiments with cultured human endothelial cells.¹³ Treated mice had less injury-related arterial thickening.¹³ The cultured cells produced more nitric oxide after treatment.¹³ These findings may guide later research, but they do not show vascular benefit in people.¹³ The manuscript was also shared before formal peer review.¹³

Labels such as “mouse,” “cell,” and “preprint” define the reach of a finding. They are not minor notes. Lab work can explore a pathway under controlled conditions. Human trials can test outcomes in enrolled groups. Observational records can describe patterns in routine documentation. Each method contributes a different piece. Strong reading keeps those pieces distinct instead of arranging them as one ladder toward certainty.

Bottom line

Mounjaro and Zepbound both name tirzepatide in their FDA records, but they use separate application numbers.¹ Their original applications also have different approval dates.³ Those points establish product identity and record history. They do not make all wording across the two labels interchangeable.

The wider research requires the same discipline. Human trials apply to defined groups and protocols.⁵ Observational records may retain confounding or documentation limits.⁸ A case report describes one person, while mouse and cell work addresses early mechanisms.¹⁰ For readers in the Philippines, keep the product, source, population, outcome, and design attached to each sentence.

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

Are Mounjaro and Zepbound one FDA product record?

No. The Zepbound label lists tirzepatide under NDA 217806.¹ The Mounjaro label lists tirzepatide under NDA 215866.² The shared molecule is an identity link between the records. It does not turn two application numbers into one file or make every label statement portable.

Why should readers check an application number?

An application number connects a statement to a named FDA product record. Zepbound uses NDA 217806, while Mounjaro uses NDA 215866.¹ Checking that number helps readers verify which label supports a date or identity claim. It is a simple guard against mixing details from separate records.

What does dual agonist mean here?

Tirzepatide activates both GIP and GLP-1 receptor signaling.⁴ The term describes a biological mechanism, not a predicted personal result.⁴ Mechanism studies can explain why researchers ask certain questions. Clinical outcomes still need suitable human trials with a defined population, comparison group, follow-up period, and outcome.

Can separate pooled analyses prove two drugs are equivalent?

No. The cited systematic review analyzed tirzepatide and semaglutide separately across 45 randomized trials.⁷ It was not one direct head-to-head trial.⁷ Its tirzepatide coronary estimates were less precise because those trials had fewer events.⁷ Equivalence needs evidence designed to test that specific question.

What can a case report tell readers?

A case report can document one person’s event, testing, and follow-up in detail. The cited report described confirmed hypersensitivity in one woman and a supervised challenge with semaglutide.¹⁰ It cannot estimate population frequency or predict another person’s response. Its value is detail, not a rate.

How should readers treat mouse, cell, and preprint findings?

Treat each label as a boundary. The cited preprint reported arterial findings in mice and nitric-oxide findings in cultured human cells.¹³ It did not establish vascular benefit in people. Preprint status also means formal peer review was not complete when the manuscript was shared.

Sources

Footnotes

1. FDA Drugs@FDA record for ZEPBOUND (TIRZEPATIDE). Authoritative US regulatory record for the named Zepbound product only; it does not establish equivalence with a catalog item. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. FDA Drugs@FDA record for MOUNJARO (TIRZEPATIDE). Authoritative US regulatory record for the named Mounjaro product only; it does not establish equivalence with a catalog item. ↩ ↩² ↩³ ↩⁴

3. FDA Drugs@FDA record for ZEPBOUND (TIRZEPATIDE); FDA Drugs@FDA record for MOUNJARO (TIRZEPATIDE). US FDA dates and separate new drug applications; these facts do not describe Philippine regulatory status. ↩ ↩² ↩³

4. Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.. Narrative review combining clinical, preclinical, and specialist literature; mechanistic statements are not themselves clinical outcome proof. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).. Randomized, double-blind, placebo-controlled monotherapy trial at 29 Chinese centers, funded by Eli Lilly; results apply to the studied population and protocol. ↩ ↩² ↩³ ↩⁴ ↩⁵

6. Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.. Prespecified patient-reported outcomes from a randomized Japanese subgroup under a trial protocol; correlation with weight loss does not establish causation. ↩ ↩² ↩³

7. Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.. Systematic review with separate pooled analyses across adults with type 2 diabetes and/or obesity; it was not a direct head-to-head trial. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

8. Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.. Observational global database study after propensity matching; residual confounding remains possible and the finding does not prove equivalence. ↩ ↩² ↩³ ↩⁴

9. Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.. Small, short, non-randomized study without direct inflammatory or platelet-function biomarkers; it cannot establish a direct platelet effect. ↩ ↩² ↩³ ↩⁴ ↩⁵

10. Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.. Single-patient case report using allergy testing and supervised challenge; it cannot estimate frequency or predict responses in other people. ↩ ↩² ↩³ ↩⁴ ↩⁵

11. Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records.. Retrospective US real-world study using an LLM-assisted, physician-adjudicated pipeline; a prescription record may reflect intent rather than confirmed exposure. ↩ ↩² ↩³ ↩⁴

12. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.. Editorial analysis of products found on compounding websites in early 2025; it did not test those products clinically or analytically. ↩ ↩² ↩³

13. Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide. Non-peer-reviewed preprint combining mouse experiments and laboratory cell work; it does not demonstrate vascular benefit in humans. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶